OVID: Ovid Therapeutics Inc. Forward P/E Multiple

Official company branding of Ovid Therapeutics (OVID)

Orphan drug status creates a monopoly, protecting the niche from players lacking massive capital. The forward P/E ratio of Ovid Therapeutics Inc. (OVID) visualizes this barrier, where the value 0.00 describes the current level of market expectations. Patents for epilepsy drugs and partnerships with tech giants strengthen the foundation, while the stable operation of certified laboratories guarantees the uninterrupted conduct of clinical trials.

OVID - Ovid Therapeutics Price to Future Earnings Ratio over the range 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Ovid Therapeutics Inc. (OVID)

- current price and projected stock value:
Fundamental valuation:Ovid Therapeutics
Product sample of Ovid Rx

The transparency of the neurological pipeline and Dr. Levin's expertise in licensing deals make the forward P/E NTM of Ovid Therapeutics Inc. (OVID) on GURU.Markets an accurate barometer of market expectations. This indicator compares current market capitalization with projected earnings, allowing investors to assess the fairness of the share price relative to future cash flows and identify anomalies in global capital flows.

Competitors of Ovid Therapeutics Inc. (OVID)

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena Corporation PLC|ALEC (alector.com) - Forward P/E Multiple|Projected Price to Earnings Annexon, Inc. (ANNX)|Future Price to Earnings Omeros Corporation (OMER)|Neurogene Inc. - Price to Future Earnings Ratio|acimmune.com - Projected Price to Earnings|Forward P/E Multiple Voyager Therapeutics Inc VYGR|NMRA - Future Price to Earnings|Forward Price to Earnings Multiple Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Future Price to Earnings|Price to Future Earnings Ratio ACOG|Future Price to Earnings Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings SAVA (Cassava)|Market Cap to Projected Earnings Assertio Therapeutics|Coya Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio VTGN (VistaGen Therapeutics Inc)|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)